7C8 Stock Chart & Stats
€0.03
-€0.03(-19.10%)
At close: 4:00 PM EST
€0.03
-€0.03(-19.10%)
Day’s Range― - ―
52-Week Range€0.02 - €0.09
Previous CloseN/A
Volume0.00
Average Volume (3M)14.00
Market Cap
€3.01M
Enterprise Value€4.97M
Total Cash (Recent Filing)€137.54K
Total Debt (Recent Filing)€627.68K
Price to Earnings (P/E)―
Beta-0.51
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding109,200,640
10 Day Avg. Volume40
30 Day Avg. Volume14
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)0.96
Price to Sales (P/S)0.00
P/FCF Ratio-2.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Capital StructureNo reported debt reduces fixed interest obligations and lowers insolvency risk, giving management flexibility to allocate scarce cash toward R&D and partner negotiations. Over a 2–6 month horizon this supports program continuity without immediate debt service pressure.
Focused Oncology PDT PipelineA clear therapeutic focus (IVX-P02 PDT for breast and GI cancers) concentrates resources and expertise, improving execution odds versus a scattered portfolio. Structural oncology demand and potential for partner-led late-stage development make this a durable strategic advantage if clinical progress continues.
Free Cash Flow ImprovementAn improving free cash flow trend, even from negative levels, signals progress in cost discipline or milestone timing. Sustained improvement over months can lengthen runway, reduce frequency of external financing, and increase optionality for strategic partnerships or focused trials.
Bears Say
Revenue Collapse & Widening LossesThe drop to zero revenue and sharply wider net loss materially weakens the company's ability to self-fund R&D, undermines commercial validation and partner leverage, and accelerates equity depletion. Over months this raises execution risk and funding urgency for clinical programs.
Persistent Negative Operating Cash FlowRepeated operating cash deficits indicate the business structurally burns cash to fund operations. Continued negative cash flow forces reliance on dilutive equity or partnership financing, creating execution uncertainty and potential interruptions to multi‑phase clinical development over the medium term.
Shrinking Equity And AssetsRapid declines in equity and total assets reduce financial flexibility and the firm's buffer against further losses. With a smaller balance sheet the company faces higher likelihood of urgent capital raises or asset sales, constraining long‑term strategic choices and partner negotiation strength.
Invion News
7C8 FAQ
What was Invion’s price range in the past 12 months?
Invion lowest stock price was €0.02 and its highest was €0.09 in the past 12 months.
What is Invion’s market cap?
Invion’s market cap is €3.01M.
When is Invion’s upcoming earnings report date?
Invion’s upcoming earnings report date is Aug 27, 2026 which is in 32 days.
How were Invion’s earnings last quarter?
Invion released its earnings results on Feb 26, 2026. The company reported -€0.026 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.026.
Is Invion overvalued?
According to Wall Street analysts Invion’s price is currently Overvalued.
Does Invion pay dividends?
Invion does not currently pay dividends.
What is Invion’s EPS estimate?
Invion’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Invion have?
Invion has 109,200,640 shares outstanding.
What happened to Invion’s price movement after its last earnings report?
Invion reported an EPS of -€0.026 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Invion?
Currently, no hedge funds are holding shares in DE:7C8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Invion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-37.10%
Trailing 12-Months
Company Description
Invion
Invion Limited, an Australian clinical-stage life sciences enterprise, is actively engaged in the research and development of photodynamic therapy (PDT) to address various cancer types. Its flagship offering, IVX-PDT, is a photosensitizer agent being developed to combat skin cancers alongside a range of solid tumors, including those affecting the lungs, prostate, ovaries, and mesothelioma. The company has forged a research and development alliance with the Hudson Institute of Medical Research, jointly pursuing R&D initiatives for its Photosoft technology across a broad spectrum of cancer treatments. Moreover, a dedicated research agreement with the Peter MacCallum Cancer Centre facilitates pre-clinical and in-vitro investigations into Invion's IVX-PDT for ano-genital cancers, such as penile and anal cancers. The firm was established in 2000 and is headquartered in Melbourne, Australia.
Technical Analysis
Percheron Therapeutics
―
Argent Biopharma
―
Medical Developments International Limited
―
Althea Group Holdings Ltd.
―
IDT Australia Limited
―